Institut de Recherche Cliniques de Montreal (IRCM) Post-COVID-19 (IPCO) Research Clinic

Primary Objectives: 1. Evaluate the short- and long-term end-organ complications post-COVID-19 in relation to the severity of the acute COVID-19 infection. 2. Establish a post-COVID-19 biobank. Secondary Objectives: Develop a model that may predict the development of end-organ complications. Primary Endpoint: The development of any end-organ complication that can plausibly be related to COVID-19. Secondary Endpoints: 1. Detection of any new abnormality on echocardiogram \>4 weeks after COVID-19 symptom-onset or diagnosis. 2. Detection of any new abnormality on pulmonary function testing (PFT) or any change in PFT compared to a pre- or post-COVID-19 baseline PFT. 3. An increase in liver enzymes \> 2X upper limit of normal that occurs post-COVID-19 and is not associated to any other process (e.g., cholestasis, drug toxicity, alcohol abuse, hepatitis A, B, C, D, E). 4. Any change in pre-COVID-19 weight, waist circumference or body mass composition. 5. Any change in HgA1C, lipid profile or thyroid stimulating hormone (TSH) from pre-COVID-19 baseline that begins or persists \>4 weeks after COVID-19 symptom-onset or diagnosis. 6. A positive fecal calprotectin or lactoferrin measurement occurring \>4 weeks after COVID-19 symptom-onset or diagnosis. 7. Any significant change in renal parameters (e.g., micro-albuminuria, serum creatinine, glomerular filtration rate \[GFR\]) detected \>4 weeks after COVID-19 symptom-onset or diagnosis. 8. Any change in physical activity and/or exercise tolerance as measured by actimeter reading or 6-minute walk test (6MWT) with ambulatory oximetry 9. Any change in well-being as measured by our WHO Well-Being Questionnaire 10. Any change in functional status as measured with the Post COVID-19 Functional Status Scale (PCFS) 11. Any change in quality of life, as measured by the European Quality of Life 5 Dimensions (EQ-5D-5L) tool 12. Any detection or exacerbation of post-exertional malaise (PEM)/post-exertional symptom exacerbation (PESE) using the DePaul Symptom Questionnaire - Post-exertional malaise (DSQ-PEM) short form and the FUNCAP27 questionnaire 13. Any detection of new (i.e., not known to be present prior to COVID-19 infection) cardiac dysautonomia using the 10-minute standing test. Methodology: Participants will have up to 5 medical visits (depending on the time since diagnosis and group) over the course of 60 months. The data will be collected for clinical monitoring and biobanking purposes. Medical visits include: * Clinical assessment * Epidemiological questionnaire * Well-being questionnaire * Physical exam (if indicated) * Vital signs * Measurement of waist circumference * Weight and height measurement * Impedance / evaluation of body mass composition * Actimeter reading * Pulmonary function test * Echocardiography * Electrocardiogram * Urine collection * Blood draw * Saliva collection * Sebum collection * Stool collection (optional) * Nasopharyngeal swab (optional)